AOC Surgical Outcome Survey

Slides:



Advertisements
Similar presentations
SURGICAL APPROACH TO GYNAECOLOGICAL CANCERS
Advertisements

Resection rate for patients with tissue confirmation of NSCLC ( :England) First seen in centre with thoracic surgery? Number With a tissue diagnosis.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
A Propensity-matched Study of Lobectomy Versus Segmentectomy for Radiologically Pure Solid Small-sized Non-small Cell Lung Cancer Terumoto Koike 1, Seijiro.
Dr.Yousefi Gynecologist Oncologist Surgical Staging Conservative Surgery Cytoreduction Surgery Optimal Cytoreduction Intraperitoneal Chemotherapy Neoadjuvant.
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Cancer Ignace Vergote, MD PhD University Hospitals Leuven, Belgium IGCS Santa.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
{ Upper Abdominal Debulking of Gynecologic Malignancies Shaun McKenzie, MD Assistant Professor of Surgery University of Kentucky.
AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4)
TRAB/2FTRAB/2O A Normal Breast Epithelium Supplemental Figure 1 iii iii iv TRAB/2FTRAB/2O GFs B M.W. None=0
Primary Debulking for Bulky Advanced Stage Ovarian Cancer Ginger J. Gardner, MD Director, Survivorship Program Gynecology Service, Department of Surgery.
Lymphadenectomy in Epithelial Ovarian Cancer
Multimodality therapy for locally advanced thymomas: a cohort study of prognostic factors from a European multicentric database Dr. GIOVANNI LEUZZI Department.
Neoadjuvant followed by interval cytoreduction Francesco Fanfani Gynecologic Oncology Dpt. Obstetrics & Gynecology Catholic University - Rome
Gynecologic Malignancies Dr. David Edelmann Sharett Institute of Oncology Hadassah Medical Organization.
EC917 Eva Gallardo, MD Medical Manager, Biocompatibles UK Drug Eluting Bead: Future Product Applications.
on behalf of the ACOSOG Z4032 Investigators
Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,
A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of newly diagnosed diffuse large B cell lymphoma Results from a UK NCRI Lymphoma.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of colorectal cancer: case report and literature review Alexandra.
Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.
14 th Annual Meeting of the Connective Tissue Oncology Society November 13-15, 2008, London, UK Oliver Zivanovic, Mario M. Leitao, Alexia Iasonos, Lindsay.
Radical surgery is the preferable treatment option for T1- 2/N0 low rectal cancer Jose G. Guillem, MD, MPH Department of Surgery Memorial Sloan Kettering.
How clinicians use data to make an impact on clinical outcomes Dr Mick Peake Clinical Lead, National Cancer Intelligence Network Consultant & Senior Lecturer.
Lulic I, Miric M, Tomicic M, Palian M, Tomasevic B, Peric M
David Cibula, VFN Innovation in surgical approach of ovarian cancer David Cibula Gynecologic Oncology Centre General Faculty Hospital in Prague.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
Claudio Zamagni e Pierandrea De Iaco Napoli 25 giugno 2015 GOGER-01 Study Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel.
The role of chemotherapy in Borderline ovarian tumors Ines Vasconcelos, MD/PhD Oncology Center Kurfurstendamm, Berlin - DE.
Management of Malignant Ovarian Germ Cell Tumors
Primary Debulking vs NACT+IDS in EOC (PFS/OAS/Morbidity)
Randomized Phase III Study Of Gemcitabine
NEOADJUVANT CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CANCER
LION (Phase III Trial): Lymphadenectomy for LN-Negative Advanced Ovarian Cancer Following Complete Resection CCO Independent Conference Highlights* of.
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
Chang-Yun Lu, Mao-Chih Hsieh
Dose dense chemotherapy in the adjuvant treatment of ovarian cancer
Short-term outcome of neo-adjuvant chemotherapy
Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues
Esophagectomy for cancer:
Case Rep Oncol 2017;10:462– DOI: /
Overzicht activiteiten werkgroep medicamenteuze therapie
Surgery in Stage IIb-IV Ovarian Carcinoma
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Amant F – Gynecological Oncology - UZ Gasthuisberg, Leuven
Peritoneal metastases can be cured
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.
Prognosis of younger patients in non-small cell lung cancer
HEPATIC RESECTION FOR PARENCHIMATOUS OVARIAN CANCER LIVER METASTASES BEYOND SECONDARY CYTOREDUCTION FOR RELPASED OVARIAN CANCER Nicolae Bacalbasa1,
Does Adenomyosis Impede Spread of Endometrial Cancer
Laparoscopic vs Open Colonic Surgery: Long Term Survival
European Urology Focus
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
Staging Cancer.
GEMSTONE Educational Case Summary
GEMSTONE Educational Case Summary
GEMSTONE Educational Case Summary
What is the role of genetic testing in patients with ovarian cancer?
Primary thymic carcinoma
A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients  Elizabeth A. David, MD, Stina W. Andersen, PhD,
GEMSTONE Educational Case Summary
Patients who have received chemotherapy (n=60)
Disease-specific survival
PDS vs NACT+İDS İn ASEOC
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.
GOCS GRUPO ONCOLÓGICO COOPERATIVO DEL SUR
Presentation transcript:

AOC Surgical Outcome Survey Characteristic Onc. Ref. Centres Other p Patients 140 65 Age: median (range) 60 (32-85) 59 (45-77) 0.16 PS: median (range) 1 (0.3) 1 (0-3) 0.85 ASA: median (range) 2 (1-4) 2 (1-3) 0.89 Preop. CA125: median (range) 727 (10-13.641) 690 (32-12.356) 0.88 Ascites: median (range) 2000 (50-10.000) 2000 (100-11.000) Histology: serous 98 (70.0) 50 (76.9) 0.32 Grade: poor 103 (73.6) 53 (81.5) 0.29 FIGO Stage: IIIC + IV 126 (90) 62 (95.4) 0.27 Bulky nodes 41 (29.3) 13 (20) 0.17

AOC Surgical Outcome Survey Scores by Pattern of Centre Onc. Ref. Centres Other p Patients 140 65 Perit. Ca. Index: mean (range) 17.2 (3-33) 15.4 (4-39) 0,79 Eisenkop S.: mean (range) 8.5 (2-15) 7.8 (2-13) 0,20 Fagotti S.: mean (range) 7.5 (0-14) 7.3 (0-14) 0.79

AOC Surgical Outcome Survey CC by Pattern of Centre Completeness of surgical cytoreduction Onc. Ref. Centres Other p Patients 140 65 CC=0 84 (60) 16 (24.6) <0,001 CC=1 18 (2.9) 7 (10.8) CC=2 9 (6.4) 21 (32.3) CC=3 29 (20.7)

AOC Surgical Outcome Survey Multivariate Analysis of CC=0 Variable Multivariate Analysis p OR (95% CI) ASA: 1-2 1 <0.05 3-4 2.98 (1.34-6.64) Peritoneal Cancer Index: < 20 > 20 4.29 (1.82-10.08) Eisenkop Score: <6 <0.001 >6 13.37 (3.81-46.93) Centre: Oncol. Referral Centre Other 11,97 (4,66-30,76)

AOC Surgical Outcome Survey Causes of CC=2-3 by Pattern of Centre .1 Cause of unsuccessful surgical cytoreduction Onc. Ref. Centres (N=38) Other (N=41) p Tumor dependent 32 (84.2) 7 (17.1) <0.001 Diffuse peritoneal carcinomatosis 24 (63.2) > 3 bowel resection required 1 (2.6) Infiltration of porta hepatis Bulky N over the renal vessels 3 (7.9) Infiltration of mesenter basis

AOC Surgical Outcome Survey Causes of CC=2-3 by Pattern of Centre .2 Cause of unsuccessful surgical cytoreduction Onc. Ref. Centres (N=38) Other (N=41) p Surgeon dependent 6 (15.8) 34 (82.9) <0.001 No or inadeguate additional surgery Diaphragm 3 (7.9) 14 (34.1) Diaphragm + RP 4 (9.8) Pelvis 2 (5.3) 5 (12.2) Pelvis + RP 2 (4.9) Diaphragm + pelvis 1 (2.6) 9 (22)